Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-10367A |
Brand: | MCE |
CAS: | 289499-45-2 |
MDL | MFCD09954112 |
---|---|
Molecular Weight | 558.86 |
Molecular Formula | C24H27Cl3FN5O3 |
SMILES | C=CC(NC1=CC2=C(N=CN=C2C=C1OCCCN3CCOCC3)NC4=CC=C(C(Cl)=C4)F)=O.[H]Cl.[H]Cl |
EGFR 7.4 nM (IC 50 ) |
ErbB2 9 nM (IC 50 ) |
Canertinib dihydrochloride (CI-1033 dihydrochloride) significantly inhibits growth of cultured melanoma cells, RaH3 and RaH5, in a dose-dependent manner. IC
50
is approximately 0.8 μM and by 5μM both cell lines are completely growth-arrested within 72 h of treatment. Incubation of exponentially growing RaH3 and RaH5 with 1 μM canertinib accumulated the cells in the G1-phase of the cell cycle within 24 h of treatment without induction of apoptosis. 1 μM canertinib inhibits ErbB1-3 receptor phosphorylation with a concomitant decrease of Akt-, Erk1/2- and Stat3 activity in both cell lines
[2]
.
Canertinib dihydrochloride also is a potent activator of exosome secretion
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Canertinib dihydrochloride (CI-1033 dihydrochloride) shows superior in vivo antitumor activity, giving growth delays in A431 xenografts exceeding 50 days following oral administration [1] . The growth of human malignant melanoma xenografts, RaH3 and RaH5, in nude mice is significantly inhibited by i.p. injections of 40 mg/kg/day canertinib (Fig. 4). The anti-proliferative effect on melanoma xenografts is visible already within 4 days of treatment and further increased throughout the treatment period as observed through the differences in tumor volumes, reaching statistical significance within 18 days of treatment [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00174356 | Pfizer |
Carcinoma, Non-Small Cell Lung
|
December 2002 | Phase 1 |
NCT00051051 | Pfizer |
Breast Neoplasms
|
December 2002 | Phase 2 |
NCT00050830 | Pfizer |
Lung Neoplasms
|
January 2003 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 62.5 mg/mL ( 111.83 mM ; Need ultrasonic)
H 2 O : 25 mg/mL ( 44.73 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.7894 mL | 8.9468 mL | 17.8936 mL |
5 mM | 0.3579 mL | 1.7894 mL | 3.5787 mL |
10 mM | 0.1789 mL | 0.8947 mL | 1.7894 mL |
Add each solvent one by one: PBS
Solubility: 10 mg/mL (17.89 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.72 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.08 mg/mL (3.72 mM); Suspended solution; Need ultrasonic
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.